S
China SXT Pharmaceuticals, Inc.
Period
FY 2026
Revenue
—
Net Income
$-6.21M
Total Assets
$34.75M
Equity
$29.71M
Shares Out
958.1K
Op. Cash Flow
$-4.02M
Business
China SXT Pharmaceuticals is a pharmaceutical company that researches, develops, manufactures, and sells Traditional Chinese Medicine Pieces (TCMP) products through its consolidated variable interest entity in Jiangsu Province, China. The company offers three main product categories: Advanced TCMP (including Directly-Oral and After-Soaking-Oral formulations), Fine TCMP, and Regular TCMP, with a portfolio of approximately 11 Advanced products, 200 Regular TCMP products, and 200 raw medicinal materials. The company distributes its products primarily to hospitals, pharmacies, and pharmaceutical distributors across five Chinese provinces including Jiangsu, Anhui, Jiangxi, Guangdong, and Hubei.
Summary from 20-F filed 2026-07-01
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 | Mar 31, 2024 2024-03-31 |
|---|---|---|---|---|
| Revenues | 1 | 2 | 2 | |
| Cost of revenues | 889,350 | 1 | 1 | |
| Gross profit | 248,702 | 367,427 | 553,971 | |
| Operating expenses: | — | — | — | |
| Selling and marketing | 244,185 | 289,859 | 433,566 | |
| General and administrative | 7 | 3 | 3 | |
| Total operating expenses | 7 | 3 | 3 | |
| Operating loss | −7 | −3 | −3 | |
| Other income (expenses): | — | — | — | |
| Interest expenses, net | 62,965 | 648,221 | 544,279 | |
| Other income (expenses), net | 980,813 | 25,048 | −39,036 | |
| Total other income (expenses), net | 917,848 | −623,173 | −583,315 | |
| Loss before income taxes | −6 | −3 | −3 | |
| Income tax expenses | — | — | — | |
| Net loss | −6 | −3 | −3 | |
| Other comprehensive loss: | — | — | — | |
| Foreign currency translation income (loss) | 877,644 | −49,727 | −828,224 | |
| Comprehensive loss | −5 | −3 | −4 | |
| Loss per ordinary share | — | — | — | |
| Basic (in Dollars per share) | −9.13 | −348.17 | −4,286 | |
| Diluted (in Dollars per share) | −9.13 | −348.17 | −4,286 | |
| Weighted average number of ordinary shares outstanding | — | — | — | |
| Basic (in Shares) | 679,648 | 9,489 | 723 | |
| Diluted (in Shares) | 679,648 | 9,489 | 723 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 |
|---|---|---|---|
| ASSETS | — | — | |
| Current Assets | — | — | |
| Cash and cash equivalents | 28 | 18 | |
| Restricted cash | 368 | 30,413 | |
| Accounts receivable, net | 931,567 | 1 | |
| Inventories, net | 777,059 | 828,053 | |
| Advance to suppliers | 2 | 301,050 | |
| Due from related parties | 4 | 835,126 | |
| Other receivables and other current assets, net | 372,392 | 319,058 | |
| Total Current Assets | 35 | 21 | |
| Non-current Assets | — | — | |
| Property, plant and equipment, net | 117,103 | 178,561 | |
| Intangible assets, net | 6,328 | 11,808 | |
| Right-of-use assets – operating leases – related party | 121,421 | 176,648 | |
| Total Non-current Assets | 244,852 | 367,017 | |
| TOTAL ASSETS | 35 | 22 | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | — | — | |
| Current Liabilities | — | — | |
| Short-term borrowings | 355,175 | 702,184 | |
| Long-term borrowings – current portion | — | 8,781 | |
| Accounts payable | 497,648 | 1 | |
| Refund liabilities | 16,563 | 53,885 | |
| Contract liabilities | 104,423 | 58,627 | |
| Accrued expenses and other liabilities | 3 | 3 | |
| Tax payable | 2,871 | 1 | |
| Operating lease liabilities – current – related party | 67,979 | 61,229 | |
| Total Current Liabilities | 4 | 6 | |
| Non-current Liabilities | — | — | |
| Long-term borrowings – non current portion | 644,390 | 96,264 | |
| Operating lease liabilities – non-current – related party | 53,442 | 115,419 | |
| Total Non-current Liabilities | 697,832 | 211,683 | |
| TOTAL LIABILITIES | 5 | 6 | |
| COMMITMENTS AND CONTINGENCIES | — | — | |
| SHAREHOLDERS’ EQUITY | — | — | |
| Ordinary shares, unlimited shares authorized, no par value, 958,077 class A ordinary shares issued and outstanding 4 class B ordinary shares issued as of March 31, 2026 (91,756 shares issued and outstanding as of March 31, 2025) | 64 | 45 | |
| Accumulated deficits | −34 | −28 | |
| Accumulated other comprehensive loss | −197,878 | −1 | |
| Total Shareholders’ Equity | 30 | 15 | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 35 | 22 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | Mar 31, 2026 2026-03-31 | Mar 31, 2025 2025-03-31 | Mar 31, 2024 2024-03-31 |
|---|---|---|---|---|
| Cash Flows from Operating Activities: | — | — | — | |
| Net loss from operations | −6 | −3 | −3 | |
| Adjustments to reconcile net loss to net cash provided by operating activities: | — | — | — | |
| Depreciation and amortization expenses | 73,668 | 82,297 | 203,247 | |
| Expected credit loss | 128,265 | 263,972 | 283,234 | |
| Allowance for long-term deposit | — | 1 | — | |
| Inventories write-down | 53,955 | −22,863 | −72,057 | |
| Loss from disposal of property, plant and equipment | — | −10,466 | — | |
| Property, plant and equipment impairment | — | — | 401,995 | |
| Construction in progress impairment | — | — | 20,929 | |
| Convertible notes - Accretion of financing cost | — | −520,787 | −292,771 | |
| Share-based compensation | 5 | — | 352,100 | |
| Depreciation of right-of-use assets | 69,551 | 69,343 | 69,819 | |
| Non-cash gain on forgiveness of income tax payable | −1 | — | — | |
| Changes in operating assets and liabilities: | — | — | — | |
| Accounts receivable | −291,134 | 257,085 | 321,422 | |
| Inventory | −36,219 | 14,530 | 219,646 | |
| Advance to suppliers | 545,809 | 287,824 | −29,356 | |
| Other receivables and other current assets | 59,438 | 223,477 | −143,175 | |
| Amount due from related parties | 2 | — | — | |
| Accounts payable | −693,481 | −114,081 | −29,254 | |
| Refund liabilities | −38,469 | −159,502 | 107,883 | |
| Contract liabilities | 40,984 | −128,813 | 30,441 | |
| Tax payable | 15,822 | −15,842 | 1,562 | |
| Operating lease liability – related party lease | −69,551 | −69,343 | −69,819 | |
| Accrued expenses and other current liabilities | 244,081 | 298,762 | −53,835 | |
| Net cash used in operating activities | −4 | −2 | −2 | |
| Cash Flows from Investing Activities: | — | — | — | |
| Purchase of property, plant and equipment | — | 2,023 | 7,063 | |
| Deposits paid for purchase of intangible assets | 1 | — | — | |
| Cash received from disposal of property, plant and equipment | — | 65,539 | — | |
| Collection of deposit - Huangshan Panjie | — | — | 33,486 | |
| Net cash (used in) provided by investing activities | −1 | 63,516 | 26,423 | |
| Cash Flows from Financing Activities: | — | — | — | |
| Proceeds from borrowings | 520,722 | 258,003 | 433,927 | |
| Repayment of borrowings | 376,563 | 78,118 | 78,654 | |
| Repayment from (Advances to) related parties | 0 | 6 | −2 | |
| Repayment to related parties | — | — | 2 | |
| Proceeds from convertible note | — | 2 | 1 | |
| Repayment of convertible notes | — | 2 | — | |
| Payment of convertible note issuance cost | — | 135,000 | 110,362 | |
| Net proceeds from shares purchase agreements | 14 | 3 | — | |
| Net cash provided by (used in) financing activities | 14 | 8 | −3 | |
| Effect of exchange rate changes on cash and cash equivalents | 881,657 | −65,091 | −765,233 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 10 | 6 | −5 | |
| Cash, cash equivalents and restricted cash at the beginning of the year | 18 | 12 | 17 | |
| Cash, cash equivalents and restricted cash at the end of the year | 28 | 18 | 12 | |
| Supplemental disclosures of cash flows information: | — | — | — | |
| Cash paid for interest expense | 21,451 | 21,239 | 24,533 | |
| Non-cash transactions: | — | — | — | |
| Issuance of shares for convertible note principal and interest partial settlement | — | 2 | 3 | |
| Non-cash settlement between balances of accounts receivable and due to related parties | — | — | 1 | |
| Non-cash settlement between balances of due from related parties and due to related parties | — | 9 | 6 | |
| Non-cash settlement between balances of long-term deposit and due to related parties | — | 7 | — | |
| Disposal of property, plant and equipment | — | 76,005 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is China SXT Pharmaceuticals, Inc.'s CIK number?
China SXT Pharmaceuticals, Inc.'s SEC CIK number is 0001723980 (1723980). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find China SXT Pharmaceuticals, Inc.'s SEC filings?
All of China SXT Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.